Severe forms of neurocysticercosis: Treatment with albeimdazole

• Autor(a) principal: Agapejev, Svetlana [UNESP]
• Data de Publicação: 1996
• Outros Autores: Da Silva, Maria Dorvalina, Ueda, Anete K.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1590/S0004-282X1996000100014; http://hdl.handle.net/11449/64750
• topic: Albendazole; Cysticercosis; Dextrochloropheniramine; Ketoprofen; Neurocysticercosis; Severe forms; Treatment; acetazolamide; albendazole; dexchlorpheniramine; ketoprofen; mannitol; adolescent; adult; clinical article; drug efficacy; female; human; male; neurocysticercosis; Adolescent; Adult; Anthelmintics; Brain Diseases; Chlorpheniramine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Tomography, X-Ray Computed

Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs Multiple symptoms were observed in 90 9% of patients. Intracranial hypertension was manifested in 90.9%. Hydrocephaly occurred in 86.4%. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used.